|
1
|
Renwick AG and Tarka SM: Microbial
hydrolysis of steviol glycosides. Food Chem Toxicol. 46 Suppl
7:S70–S74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Purkayastha S, Pugh G Jr, Lynch B, Roberts
A, Kwok D and Tarka SM Jr: In vitro metabolism of rebaudioside B,
D, and M under anaerobic conditions: Comparison with rebaudioside
A. Regul Toxicol Pharmacol. 68:259–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Toskulkac C, Chaturat L, Temcharoen P and
Glinsukon T: Acute toxicity of stevioside, a natural sweetener, and
its metabolite, steviol, in several animal species. Drug Chem
Toxicol. 20:31–44. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moons N, De Borggraeve W and Dehaen W:
Stevioside and steviol as starting materials in organic synthesis.
Curr Organic Chem. 16:1986–1995. 2012. View Article : Google Scholar
|
|
5
|
EFSA Panel on Food Additives and Nutrient
Sources (ANS), . Scientific Opinion on safety of steviol glycosides
for the proposed uses as a food additive. EFSA Journal. 8:15372010.
View Article : Google Scholar
|
|
6
|
Ge Y, Wang Y, Pang L, Zhang L, Zhai Y and
Zhou H: Proliferation, apoptosis, and invasion effects of mistletoe
alkali on human osteosarcoma U2OS in vitro. Int Surg. April
25–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Zhu X, Li H, Li B, Sun L, Xie T,
Zhu T, Zhou H and Ye Z: Piperine inhibits proliferation of human
osteosarcoma cells via G2/M phase arrest and metastasis by
suppressing MMP-2/-9 expression. Int Immunopharmacol. 24:50–58.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ottaviani G and Jaffe N: The Epidemiology
of Osteosarcoma = Pediatric and Adolescent Osteosarcoma. Jaffe N,
Bruland OS and Bielack S: Springer US; pp. 3–13. 2010
|
|
10
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: an analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rejniak KA, Lloyd MC, Reed DR and Bui MM:
Diagnostic assessment of osteosarcoma chemoresistance based on
Virtual Clinical Trials. Med Hypotheses. 85:348–354. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-Where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hattinger CM, Pasello M, Ferrari S, Picci
P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert
Opin Emerg Drugs. 15:615–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Janeway KA and Grier HE: Sequelae of
osteosarcoma medical therapy: A review of rare acute toxicities and
late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Muñoz A, Alfaro J, Pardo N, García-Miguel
P, Quintero V, Gros L, Melero C, Antuña MJ, Ocete G, de Las Heras
J, et al: Long-term results of the Spanish Protocol SO-95 for the
treatment of non-metastatic high-grade osteosarcoma of the
extremities in children. Clin Transl Oncol. 11:387–392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao S, Lu N, Chai Y and Yu X: Rapamycin
inhibits tumor growth of human osteosarcomas. J Buon. 20:588–594.
2015.PubMed/NCBI
|
|
18
|
Lu M, Huang W, Bao N, Zhou G and Zhao J:
The flavonoid ampelopsin inhibited cell growth and induced
apoptosis and G0/G1 arrest in human osteosarcoma MG-63 cells in
vitro. Pharmazie. 70:388–393. 2015.PubMed/NCBI
|
|
19
|
Lee DH, Qi J, Bradner JE, Said JW, Doan
NB, Forscher C, Yang H and Koeffler HP: Synergistic effect of JQ1
and rapamycin for treatment of human osteosarcoma. Int J Cancer.
136:2055–2064. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maugg D, Rothenaigner I, Schorpp K,
Potukuchi HK, Korsching E, Baumhoer D, Hadian K, Smida J and
Nathrath M: New small molecules targeting apoptosis and cell
viability in osteosarcoma. PLoS One. 10:e01290582015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng ZJ, Wu N, Liu Y, Shu KJ, Zou X, Zhang
RX, Pi CJ, He BC, Ke ZY, Chen L, et al: Evodiamine inhibits the
proliferation of human osteosarcoma cells by blocking PI3K/Akt
signaling. Oncol Rep. 34:1388–1396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Ji Y, Hu Z, Jiang H, Zhu F, Yuan H
and Lou H: Riccardin D induces cell death by activation of
apoptosis and autophagy in osteosarcoma cells. Toxicol in Vitro.
27:1928–1936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boonkaewwan C, Ao M, Toskulkao C and Rao
MC: Specific immunomodulatory and secretory activities of
stevioside and steviol in intestinal cells. J Agric Food Chem.
56:3777–3784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuajit C, Muanprasat C, Gallagher AR,
Fedeles SV, Kittayaruksakul S, Homvisasevongsa S, Somlo S and
Chatsudthipong V: Steviol retards renal cyst growth through
reduction of CFTR expression and inhibition of epithelial cell
proliferation in a mouse model of polycystic kidney disease.
Biochem Pharmacol. 88:412–421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takasaki M, Konoshima T, Kozuka M, Tokuda
H, Takayasu J, Nishino H, Miyakoshi M, Mizutani K and Lee KH:
Cancer preventive agents. Part. 8:Chemopreventive effects of
stevioside and related compounds. Bioorg Med Chem 17: 600–605.
2009.
|
|
26
|
Shen J, Park HS, Xia YM, Kim GS and Cui
SW: The polysaccharides from fermented Ganoderma lucidum mycelia
induced miRNAs regulation in suppressed HepG2 cells. Carbohydr
Polym. 103:319–324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Plumb JA: Cell sensitivity assays: The MTT
assay = Cancer Cell Culture. Springer; pp. 165–169. 2004
|
|
28
|
Li X, Wu WK, Sun B, Cui M, Liu S, Gao J
and Lou H: Dihydroptychantol A a macrocyclic bisbibenzyl
derivative, induces autophagy and following apoptosis associated
with p53 pathway in human osteosarcoma U2OS cells. Toxicol Appl
Pharmacol. 251:146–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cappadone C, Stefanelli C, Malucelli E,
Zini M, Onofrillo C, Locatelli A, Rambaldi M, Sargenti A, Merolle
L, Farruggia G, Graziadio A, et al: p53-dependent and
p53-independent anticancer activity of a new indole derivative in
human osteosarcoma cells. Biochem Biophys Res Commun. 467:348–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diehl JA: Cycling to cancer with cyclin
D1. Cancer Biol Ther. 1:226–231. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martin S, Reutelingsperger C, McGahon AJ,
Rader JA, van Schie RC, LaFace DM and Green DR: Early
redistribution of plasma membrane phosphatidylserine is a general
feature of apoptosis regardless of the initiating stimulus:
Inhibition by overexpression of Bcl-2 and Abl. J Exp Med.
182:1545–1556. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zinkel S, Gross A and Yang E: BCL2 family
in DNA damage and cell cycle control. Cell Death Differ.
13:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
